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Daptomycin is an antibiotic that is being used with increasing frequency for the treatment of
methic i l l in res i s tant Staphylococcus aureus (MRSA) infect ions . We report a
65-year-old male patient with vertebral osteomyelitis due to MRSA who developed acute respi-
ratory failure secondary to eosinophilic pneumonia after starting daptomycin therapy. Bron-
choscopy showed a bronchoalveolar lavage (BAL) with 33% eosinophilia and the
transbronchial biopsies revealed organizing pneumonia with many eosinophils. The patient re-
sponded rapidly to drug cessation and steroid therapy. Eosinophilic pneumonia is a rare but
potentially serious complication of daptomycin therapy that, if recognized early, responds
quickly to drug cessation and steroid therapy.
ª 2008 Elsevier Ltd. All rights reserved.The eosinophilic lung diseases are a heterogenous group
of disorders characterized by an increased number of
eosinophils within in the lung. Allen and Davis described
the most recent classification of these diseases which
includes drug induced eosinophilic lung disease.1 In this
report we present a case of daptomycin induced
eosinophilic pneumonia resulting in acute respiratory
failure.9 323 5045; fax: þ1 859 257
E.S. Bensadoun).
ll rights reserved.Case presentation
A 65-year-old man was admitted with vertebral osteomye-
litis due to methicillin resistant Staphylococcus aureus
(MRSA) and complicated by an epidural abscess. His past
medical history was significant for obstructive sleep apnea,
coronary bypass surgery, and hypothyroidism; he denied
any history of asthma and was a non-smoker. Treatment
was initiated with vancomycin and rifampin. Four weeks
into his hospitalization, he was felt to be failing medical
therapy based on progressive changes on his MRI, so van-
comycin was replaced by daptomycin 1000 mg (6 mg/kg)
daily and rifampin was continued. Other medications at
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thyroxine, pantoprazole, aspirin, and subcutaneous
heparin.
One week after starting daptomycin the patient had
a white blood cell (WBC) count of 8.0 k/ml and had devel-
oped a peripheral eosinophilia of 7%; he remained afebrile
and had no respiratory symptoms. About one week later he
began developing shortness of breath and within 24 h he
had progressed to respiratory failure requiring mechanical
ventilation. He was afebrile and his white blood cell (WBC)
count was 8.6 k/ml with 7% eosinophilia. A chest radiograph
showed diffuse patchy bilateral airspace disease (Fig. 1A),
and a right heart catheterization revealed a normal
pulmonary capillary wedge pressure. Bronchoscopy was
performed and the bronchoalveolar lavage (BAL) culture
grew Pseudomonas aeruginosa. Antibiotics at this time
included, levofloxicin, meropenem, and tobramycin.
During the next 10 days he had intermittent low grade
fever with persistent eosinophilia ranging from 6 to 10%, his
chest radiograph remained unchanged, and he continued to
require mechanical ventilation. A CT scan showed diffuse
bilateral airspace sparing the bases disease with someFigure 1 A) Chest radiograph showing bilateral airspace
disease. (B) CT chest obtained 10 days later shows persistent
bilateral airspace disease with some peripheral predominance.peripheral predominance, and small bilateral pleural effu-
sions (Fig. 1B). A repeat bronchoscopy with transbronchial
biopsies was performed. The BAL showed a WBC count of
725/ml with 33% eosinophilia, and the biopsies showed
organizing pneumonia with many eosinophils. Occasional
multinucleated giant cells were also noted; however, no
well formed granulomas or vasculitis was seen. All cultures
for bacteria, fungi, and mycobacteria were negative. The
daptomycin was immediately discontinued and methyl-
prednisolne 100 mg IV every 8 h was started; all other
medications were continued. Within 72 h, his oxygenation
and the chest radiograph had significantly improved
(Fig. 2). Over the next three days the patient was weaned
from mechanical ventilation.
The patient was discharged from hospital three weeks
later and tapered off steroids over the next six weeks.
A follow-up CT scan 3 months later was completely normal.
Discussion
Many drugs have been associated with eosinophilic
pneumonia; however, antibiotics and non-steroidal anti-
inflammatory drugs are amongst the most common.2,3
A complete and updated list of drugs suspected of causing
lung disease can be found at a web site maintained by the
Groupe Etude de la Pathologie Pulmonaire Iatrogene at
www.pneumotox.com.
The clinical presentation of drug induced eosinophilic
pneumonia may be similar to other forms of eosinophilic
lung diseases.2,3 A subacute presentation with cough and
dyspnea lasting weeks or months may be confused with
chronic eosinophilic pneumonia (CEP) while a more acute
presentation with fever, dyspnea, hypoxemia and diffuse
airspace disease on chest radiograph occurring shortly after
being exposed to the drug is more similar to acute eosino-
philic pneumonia (AEP). Peripheral eosinophilia may be
present with drug induced eosinophilic pneumonia and isFigure 2 Chest radiograph 72 h after stopping daptomycin
and starting steroids showing significant resolution of bilateral
infiltrates.
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does not exclude the possibility. On imaging, drug induced
eosinophilic pneumonia most often manifests as areas of
consolidation and ground glass opacity usually involving the
outer third of the lungs,4 a pattern very similar to CEP. In
a study on the diagnostic accuracy of CT imaging in eosin-
ophilic lung disease, a correct CT diagnosis of drug induced
eosinophilic pneumonia was made in only 27% of those who
had drug induced eosinophilic pneumonia.5
To attribute eosinophilic pneumonia to a drug, the
following conditions should be met: the diagnosis of simple,
acute, or chronic eosinophilic pneumonia must be made by
the usual criteria (BAL eosinophilia usually>25%), the
presence of a likely drug and a temporal relationship with
the onset of findings, no other cause of pulmonary eosino-
philia may be present (i.e., parasites or fungal infection),
clinical improvement after cessation of the drug, and
recurrence of eosinophilic pneumonia after rechallenge
with the drug. In most cases, rechallenge is unnecessary
and potentially dangerous.2,3
In addition to our case, two other cases of eosinophilic
pneumonia implicating daptomycin have been previously
reported.6,7 The first case described an acute onset of
respiratory symptoms one week after starting daptomycin.
The patient subsequently developed respiratory failure and
bronchoscopy revealed a BAL eosinophilia of 26%; no
peripheral eosinophilia was reported. Daptomycin was
stopped, steroids were started, and the patient improved
rapidly.6 The second case described a patient with
a gradual onset of constitutional symptoms 4e6 weeks after
starting daptomycin. CT scan revealed ill-defined nodules
and CT guided biopsy revealed organizing pneumonia with
some eosinophilic infiltrate. No BAL was performed. The
daptomycin was stopped and the symptoms improved over
several weeks.7Daptomycin is a cyclic lipopeptide antibiotic with in
vitro activity against a broad spectrum of gram-positive
bacteria, including isolates resistant to methicillin and
vancomycin.8 These types of serious infections are partic-
ularly common in patients in the intensive care unit setting,
so it is important for intensivists and pulmonologists to be
aware of this potential drug induced lung toxicity due to
daptomycin.Conflict of interest statement
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